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ABSTRACT
In utero hematopoietic stem cell transplantation (IUHCT) is a potential therapeutic alternative to postnatal
hematopoietic stem cell transplantation (HSCT) for congenital hematologic disorders that can be diagnosed
early in gestation and can be cured by HSCT. The rationale is to take advantage of normal events during hema-
topoietic and immunologic ontogeny to facilitate allogeneic hematopoietic engraftment. Although the rationale
remains compelling, IUHCT has not yet achieved its clinical potential. Achieving therapeutic levels of engraft-
ment by IUHCT alone remains challenging. However, considerable experimental progress has been made
toward the clinical strategy of using IUHCT to induce donor-specific tolerance to facilitate a relatively nontoxic
postnatal HSCT. Because donor specific tolerance induction requires relatively minimal engraftment, this strat-
egy may hold the key to broad clinical application of IUHCT in the near future.
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Hematopoietic stem cell transplantation (HSCT)
represents the only curative therapy for many hemato-
logic disorders. However, in the absence of a matched
donor, standard protocols for HSCT entail consider-
able morbidity and mortality. In utero hematopoietic
stem cell transplantation (IUHCT) is a potential non-
myeloablative alternative to HSCT for congenital
hematologic disorders that can be diagnosed early in
gestation. Through advances in prenatal screening
and molecular-based diagnostics, the opportunity for
fetal intervention is greater than ever before. The po-
tential advantages of IUHCT over postnatal HSCT
are largely based on the immunologic immaturity of
the early gestational fetus, providing the opportunity
for induction of donor-specific tolerance to allogeneic
cells. The phenomenon of fetal tolerance can poten-
tially eliminate the requirement for immunosuppres-
sion with its associated morbidity. The potential
clinical impact of IUHCT is enormous when we con-
sider the possibility that any disorder that can be prena-tally diagnosed, and can be treated by HSCT, might be
optimally treated by IUHCT.
Despite the unique opportunities offered by the fetal
microenvironment, the clinical promise of IUHCT re-
mains unfulfilled. Levels of engraftment have been
well below what might be expected to be therapeutic
for most hematologic diseases, and clinical success has
been limited to X-linked severe combined immunodefi-
ciency (XSCID). However, experimental and clinical
work over the past 2 decades has resulted in a greater un-
derstanding of the complexity of the fetal microenvi-
ronment and the obstacles it presents to successful
engraftment. In this review we will examine the rationale
and the experimental and clinical progress that has been
made in IUHCT. In addition, we will discuss our view of
the primary barriers to engraftment and discuss promis-
ing strategies with the potential to overcome them.
RATIONALE
The potential advantages of IUHCT are based upon
unique events that occur during normal hematologic729
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engraftment of transplanted allogeneic hematopoietic
stem cells (HSC). The phenomenon of fetal immuno-
logic tolerance, first introduced by Billingham et al.
[1], is perhaps the most important advantage of IUHCT
over postnatal SCT. The fetal thymic microenviron-
ment plays a primary role in the determination of
self-recognition and the repertoire of response to for-
eign antigens. Pre-T cells undergo positive and nega-
tive selection during a series of maturational steps in
the fetal thymus that are controlled by thymic stromal
and dendritic cells [2-4]. The end result is the deletion
of T cell clones with high affinity for self-antigen, and
preservation of a T cell repertoire against foreign anti-
gen. Therefore, introduction of foreign antigen prior to
thymic processing should, in theory, result in presenta-
tion of donor antigen in the thymus with clonal dele-
tion of alloreactive T cells. Although the concept of
fetal tolerance remains valid, it has become apparent
that it is not an all-or-none phenomenon. Self-reactive
T cells are known to escape thymic deletion in signifi-
cant numbers and to be controlled by regulatory mech-
anisms, including T regulatory cell populations, that
are essential for prevention of autoimmune disease
[5-7]. In the context of IUHCT, this relatively new
knowledge has important implications that will be
discussed below.
A second potential biologic advantage of IUHCT is
that the early gestational period is the only time in life
during which the large-scale migration of stem cells to
tissue compartments normally occurs. The hematopoi-
etic system is the prototypical example. Hematopoiesis
shifts from the yolk sac, placenta, and AGM region, to
the fetal liver and finally to the bone marrow [8-10]. Al-
though this was once naively thought to provide ‘‘space’’
in the expanding hematopoietic compartment, it is now
apparent that the fetal hematopoietic compartment is
highly competitive, containing an excess of circulating
HSCs to occupy developing niches. Nevertheless, if
one could understand and utilize the natural mecha-
nisms that normally regulate migration and engraftment
of native HSC, one might achieve a selective advantage
for donor cells. The third major advantage of the fetus
compared to the adult is its relatively small size. At 12
weeks’ gestation, the human fetus weighs\35 g. There-
fore, much higher relative doses of stem cells can be
transplanted, favoring successful engraftment. Finally,
prenatal SCT offers the potential to preempt early dis-
ease manifestations and prevent the end-organ damage
and severe treatment-associated morbidity of postnatal
HSCT.
EXPERIMENTS OF NATURE
Hematopoietic chimerism between nonidentical,
dizygotic twins with shared placental circulation has
been observed in multiple species, including cattle,goats, and primates [11-14]. This phenomenon was
first described by Owen in 1945 [13] after he observed
that dizygotic cattle twins that share crossplacental cir-
culation were born chimeric for their siblings’ blood
elements. These natural chimeras exhibit specific im-
munologic tolerance and maintain stable levels of he-
matopoietic chimerism for life. Specifically, dizygotic
twin cattle have been shown to be immunologically tol-
erant of their sibling by mixed lymphocyte cultures and
renal and skin allografts [15,16]. These ‘‘experiments of
nature’’ are proof in principle supporting the potential
of IUHCT to achieve mixed allogeneic chimerism with
associated donor specific tolerance.
Of relevance to clinical application, the existence
of chimerism in human [11,17] and nonhuman primate
[14,18] twins is well documented. In the case of dizy-
gotic human twins, the frequency of chimerism is rel-
atively high (8% for twins and 21% for triplets) [17],
and levels of chimerism in some cases have been at
a level that would be therapeutic for most hematologic
diseases [19]. These findings have long provided proof
of principle for the therapeutic potential of IUHCT.
However, because natural chimeras result from the
mixing of hematopoietic cells via placental vascular
anastomoses, the exposure to allogeneic blood compo-
nents occurs continuously and begins very early in ges-
tation, which is difficult to replicate experimentally.
EXPERIMENTAL PROGRESS—ANIMALS
IUHCT has been studied in a variety of animal
models over the past 30 years. The first experimental
success with IUHCT utilized transplacental injection
of donor BM cells at E11 into anemic fetal mice with
a stem cell deficiency based on the absence of c-kit
[20]. In these studies, the degree of erythroid replace-
ment correlated with the degree of underlying anemia,
with complete early replacement by donor erythroid
cells in lethally anemic homozygous mice. This was
the first example of the general principal that IUHCT
can be highly successful in model systems or diseases
entailing a competitive or survival advantage for donor
cells. Later studies by Blazar et al. [21] demonstrated
the ability to achieve multilineage chimerism in anemic
recipients, as well as the ability to achieve lymphoid
reconstitution in the mouse severe combined immuno-
deficiency (SCID) model [22,23]. Thus, in the presence
of a lineage deficiency, IUHCT was able to reconsti-
tute the defective lineage; however, it appeared that
competitive pressure from the normal host lineages
prevented multilineage donor cell expression. The
presence of an immune deficiency also appears to favor
engraftment. IUHCT in the nonobese diabetic
(NOD)/SCID mouse model, in which there are addi-
tional defects in natural killer (NK) cells as well as
antigen presentation [24] resulted in multilineage
engraftment [25]. These studies demonstrated the
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IUHCT by circumstances of competitive advantage,
immune deficiency, or both.
Results after allogeneic IUHCT in normal animal
models have been more variable. The most encourag-
ing data has been generated in the ovine model, where
early gestational transplantation of allogeneic HSCs
into normal sheep fetuses results in sustained multili-
neage hematopoietic chimerism [26,27]. The fetal
sheep model is also permissive for xenogeneic engraft-
ment, as persistent, multilineage hematopoietic chi-
merism has been documented after transplantation of
human-derived HSCs [28,29]. Recently, the pig model
has also been successfully utilized for IUHCT. Using
Swine Lymphocyte Antigen (SLA) mismatched pigs
and a technique of T cell depletion and whole BM
add back (to achieve 1.5% T cell content) stable and
measurable multilineage chimerism was achieved [30]
with associated tolerance for SLA donor-matched kid-
ney grafts [31]. Other normal large animal models such
as the primate [32,33], goat [34], and dog [35] have
shown much greater resistance to engraftment, with
significantly lower levels of chimerism.
Over the past few years, significant experimental
progress has been made in the murine model, which
was previously highly resistant to engraftment [36-
38]. Specifically, mixed hematopoietic chimerism
across full MHC barriers with associated donor spe-
cific tolerance has been achieved [38-40]. With greater
understanding of the requirements for engraftment
[41] and the mechanisms of tolerance after IUHCT
[42], strategies have been developed that achieve high
level or complete donor chimerism across full MHC
barriers in the mouse without the need for immuno-
suppression or myeloablation [43-45]. However, de-
spite recent successes, the efficiency of engraftment
in animal model systems remains low and, in mice,
somewhat strain dependent, raising the challenge of
how to achieve consistent donor cell engraftment after
IUHCT.
BARRIERS TO PRENATAL ENGRAFTMENT
It is obvious from the preceding discussion that,
despite the unique opportunities offered by the fetal
microenvironment, there are also unique challenges
to overcome. The primary issue is that IUHCT, at
the present time, must be performed without any mye-
loablative conditioning. Because of the developmental
status of the fetus and the potential repercussions of
any pharmacologic toxicity on the fetus and mother,
standard conditioning agents cannot be utilized. In
the absence of an entirely nontoxic and hematopoietic
specific myeloablative approach, success in IUHCT
will require novel strategies to selectively engraft
donor cells. Although the rationale for IUHCT re-
mains compelling, specific barriers prevent IUHCTfrom achieving its clinical potential. These barriers
can best be understood in the context of 3 broad cate-
gories: receptivity of the host hematopoietic compart-
ment, competition from host hematopoietic cells, and
immunologic barriers to engraftment [46].
Receptivity of the Host Hematopoietic
Compartment
The concept of receptivity with regard to the host
hematopoietic compartment refers to the historic
assumption that there is ‘‘space’’ available in the ex-
panding fetal hematopoietic compartment that is avail-
able for homing and engraftment of donor cells.
However, current evidence disproves this assumption
and suggests that the fetus is far less receptive to en-
graftment of donor cells than postnatal myeloablated
or congenic nonmyeloablated recipients. In theory,
IUHCT offers the opportunity to engraft cells utilizing
the natural mechanisms that normally allow migration
and engraftment of native HSC. In the early gestational
period, hematopoiesis shifts from the yolk sac, pla-
centa, and AGM region, to the fetal liver and finally
to the bone marrow. During this time, there is an expo-
nential expansion of the hematopoietic compartment
with presumably continuous formation of new niches
for engraftment of circulating HSC. Therefore, it has
been assumed that the number of niches available for
engraftment in the prenatal microenvironment exceeds
the availability of niches in the postnatal environment;
however, a number of studies have challenged this
assumption.
A relatively valid postnatal model for comparison is
the nonmyeloablated syngeneic mouse model. In this
model the concept of ‘‘space’’ represents a dynamic equi-
librium of stem cell cycling and occupation of niches.
Studies in this model, in which the postnatal hematopoi-
etic compartment has not been irradiated and donor and
recipient cells are genetically equal, have shown a dose-
dependent increase in donor cell engraftment with
repetitive large doses of syngeneic donor BM cells
[47,48]. These studies suggest that there is a steady state
of open receptive sites in normal, nonmyeloablated BM,
and that donor cells can displace host cells over time
[49]. How does the IUHCT prenatal environment com-
pare with the nonmyeloablated postnatal environment?
The only comparable data available is for long-term en-
graftment, which reflects the relative proportion of host
HSC displaced by donor HSC over time. Interestingly,
IUHCT of 20  106 congenic BM cells [50] results in
lower engraftment levels than 40  106 syngeneic BM
cells in the postnatal nonmyeloablative model [47]
(6%-8% versus 11%, respectively). This represents ap-
proximately 50 times the cell dose on a per kilogram ba-
sis in the fetus arguing against any receptive advantage
for the fetus. However, long-term engraftment reflects
multiple parameters including homing, engraftment,
and subsequent competitive capacity of the donor cells.
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cells in the fetus we have performed detailed homing
studies in the murine model of IUHCT at a develop-
mental time point when the only receptive hematopoi-
etic site is the fetal liver (E14). In 2 separate studies
using different routes of administration (intraperitoneal
and intravenous) we have documented an engraftment
efficiency in the fetal liver for whole BM of \5%
[41,51], and for highly enriched HSC (intravenous
administration) of only 0.43% [51].
Logically, the availability of niches for donor cell
engraftment in the fetus will ultimately depend on
the balance between the expansion of circulating he-
matopoietic precursors and the formation of new stro-
mal receptive sites. Although Wolf et al. [52] observed
that stroma formation precedes hematopoiesis in the
fetal liver and BM, he also noted that hematopoietic
activity increases very rapidly after the establishment
of stroma. A later study demonstrated that the number
of HSC and progenitors circulating in fetal peripheral
blood is much higher than the number in cord blood,
or after birth, supporting the notion of relative HSC
excess [53]. In summary, there is little or no evidence
that the fetal environment has any significant receptive
advantage that facilitates IUHCT.
Competition from Host Hematopoietic Cells
Unlike the myeloablated postnatal recipient, the
fetal recipient after IUHCT maintains a vigorous he-
matopoietic compartment. Therefore, the success of
IUHCT relies on the assumption that donor HSC
can effectively compete with host HSC to achieve sig-
nificant donor cell expression. However, there is abun-
dant evidence that host hematopoietic competition is
a formidable barrier to successful engraftment after
IUHCT. Experimental evidence supports the notion
that when donor cells have a competitive advantage,
even the engraftment of a relatively limited number
of cells could ultimately reconstitute the recipient.
The extreme example of this concept is seen in c-kit-
deficient mouse strains that have a proliferative defect
in host HSC. In this model, as few as 1 or 2 normal
HSC were shown to fully reconstitute the hematopoi-
etic compartment after IUHCT [54]. However, the
converse is also true; that is, when the host cells have
a proliferative advantage, engrafted donor cells are
unlikely to expand. The proliferative and competitive
advantages of fetal liver cells [55-58] and cord blood
cells [53,59,60] over adult-derived populations are
well documented and likely represent a major impedi-
ment to expansion of the donor cell compartment
when adult donor cells are utilized.
Another relevant observation to IUHCT comes
from the allophenic mouse model, in which chimerism
is artificially created at the blastocyst level. In this
model when donor strains genetically differ withrespect to HSC cycling, the more rapidly cycling pop-
ulation will emerge as the dominant hematopoietic
contributor [61-63]. These experiments have shown
that in a chimeric microenvironment in which allo-
geneic cells compete, the level of hematopoietic expres-
sion is a function of the genetically defined competitive
capacity of the HSC.
Another study supporting the overriding impor-
tance of competitive capacity when 2 stem cell popula-
tions coexist was performed in the previously discussed
syngeneic nonmyeloablated mouse model. The model
was modified by exposure of the host to minimally
myeloablative radiation. This was followed by trans-
plantation of syngeneic donor cells that were either
nonirradiated or had received the same dose of radia-
tion as the host [64]. Transplantation of irradiated
donor cells reduced engraftment 7-fold, supporting
the concept that it is primarily the ability of donor or
recipient cells to compete, rather than mere space,
which determines successful engraftment. Therefore,
it appears that after IUHCT engraftment is limited
first by a lack of open receptive sites because of the rel-
ative excess of fetal HSC, and subsequently, the ability
of the limited number of engrafted donor cells to ex-
pand is a function of their competitive capacity relative
to the host. Given the rapid cycling and expansion ki-
netics of fetal HSC relative to adult HSC, it is not sur-
prising that the most common finding after IUHCT of
adult BM cells is low-level mixed chimerism at best. An
example of the extent of this competition is provided
by the murine congenic IUHCT model in which
very large doses of donor cells can be delivered directly
and reliably into the intravascular system at E14. In
this model, 100% of the recipients maintain long-
term donor cell multilineage chimerism. However,
even with i.v. delivery of massive doses of donor BM
cells (2  1011 cells/kg fetal wt.), the levels of mixed
chimerism are generally well under 10% [50]. Thus,
in the absence of any immune considerations or selec-
tive advantage for donor cells, host cell competition
limits the level, but not the frequency, of chimerism.
The Immune Barrier to IUHCT
It was stated earlier that fetal immunologic toler-
ance is perhaps the most important advantage of
IUHCT over postnatal SCT. Yet there has been
ongoing controversy regarding the significance of
an immune barrier to IUHCT. There are a number
of indirect arguments supporting an immunologic
barrier to engraftment. The fact that the only suc-
cessful clinical results have been achieved in an
immunodeficiency disorder [65-68] is suggestive, al-
though it is also a disorder that provides a competitive
advantage for normal cells. It is also concerning that
immunologically active T cell populations in the
human fetus have been documented at relatively early
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been shown to contain NK cells as well as T cells that
have undergone T cell receptor (TCR) rearrangements
and are alloreactive against MHC in vitro [69-72]. In
addition, the possibility of a maternal contribution to
the immunologic barrier was recently raised when im-
munologically active cells of maternal origin were
tracked to fetal tissues [73]. In a study that may be
highly relevant in the context of maternal sensitization
to donor cells, maternal autoantibody response has
been demonstrated to trigger T cell-mediated neonatal
autoimmune disease [74]. Finally, recent studies in
which fetal immunosuppression resulted in a 4- to 5-
fold increase in chimerism also suggest an immune bar-
rier [75]. Historically, the overriding argument against
the presence of an immune barrier was the lack of evi-
dence for an engraftment advantage for congenic over
allogeneic cells. In an early study, Fleischman and
Mintz [76], using transplacental injection, found in-
creased engraftment for adult BM in MHC matched
relative to mismatched c-kit-deficient mice. In this
study, however, engraftment could only be achieved
in severely anemic mice, and the observation did not
apply to fetal liver, which engrafted equally well inde-
pendent of MHC mismatch. They attributed this
difference to developmental acquisition of MHC re-
striction in adult HSC. In contrast, Howson-Jan et al.
[77], using intraperitoneal (i.p.) injection into normal
recipients, found a higher incidence of engraftment
using allogeneic (5.2%) compared to congenic (0.7%)
donors. The results of this study were limited by
a low efficiency of engraftment in both groups and
the fact that the engraftment was transient. Carrier
et al. [36] demonstrated a slightly higher rate of poly-
merase chain reaction detectable, microchimerism in
PB of congenic (25%) versus allogeneic (7%) recipients
after IUHCT, but no differences in the frequency
of organ engraftment. Recently, using mucopolysa-
charidosis type VII (MPS-VII) mice, Barker et al.
[78] demonstrated persistence of congenic cells using
a histologic marker for the enzyme b-glucuronidase
(GUSB) in peripheral tissues, but negligible levels of
congenic or allogeneic chimerism in the PB. The min-
imal chimerism and low incidence of engraftment in
these studies make interpretation of HSC engraftment
difficult. In our own laboratory, with over a decade of
experience in the murine model, we, until recently
[50], have never documented an advantage for congenic
BM engraftment. When considered with the experi-
mental observations cited above, which clearly demon-
strated that at least in some circumstances, allogeneic
and even xenogeneic cells could engraft, persist, and in-
duce associated donor specific tolerance, the presence
of a significant immune barrier seemed unlikely.
However, it is important to note that the mecha-
nism of central thymic tolerance was defined primarily
in TCR transgenic mice, in which thymic maturationof lymphocytes occurs in an environment of high-level
expression of TCR with high affinity for a specific
self-antigen, which is expressed throughout thymic
development [79-81]. This is distinct from the micro-
environment following IUHCT, in which there is
relatively late presentation of allogeneic antigen inter-
acting with recipient TCRs of varying frequency and
affinity for donor antigen. Therefore, the question re-
mained as to whether IUHCT could recapitulate im-
munologic ontogeny. In the murine model we have
examined the relationship between engraftment, tol-
erance, and the presence or absence of clonal deletion
utilizing the mammary tumor virus (mtv) oncogenes.
When engraftment is successful in the murine model,
tolerance is associated with at least partial deletion of
donor reactive lymphocytes [39,42-44], supporting
the concept that for T cell-mediated mechanisms,
IUHCT could recapitulate normal mechanisms of
self-tolerance.
However, all of these studies were done in the i.p.
model, where donor cell doses were limited and there
were lingering questions raised by the fact that levels of
engraftment in mice were somewhat strain dependent,
and by the fact that even when it was clear that equiv-
alent doses of cells were transplanted, only a fraction of
recipients engrafted. The question of allogeneic versus
congenic engraftment after IUHCT was then reex-
amined utilizing intravascular (i.v.) injection of donor
cells via the vitelline vein, a technique that allows deliv-
ery of much higher doses of cells. These studies
showed that despite equivalent homing and initial
engraftment, by 5 weeks after injection only 30% of
allogeneic animals remained chimeric and went on to
become long-term chimeras, whereas 100% of con-
genic animals maintained their engraftment [50],
definitively supporting, at least in mice, the presence
of an immune barrier to engraftment. The question re-
mains whether this immune barrier is related to some
component of innate immunity versus an adaptive im-
mune response. Because all congenic and allogeneic
animals maintained measurable levels of chimerism
at 2 weeks after IUHCT, it seems that loss of engraft-
ment is a postnatal event, and because the innate im-
mune system should cause earlier loss of allogeneic
engraftment, this data supports the existence of a previ-
ously unrecognized adaptive immune barrier after
IUHCT. The mechanisms involved in this barrier
remain to be defined. We have hypothesized, but not
yet proved, that donor reactive T cells escape thymic
deletion because of inadequate or late presentation of
donor antigen in the thymus. These cells either reject
the graft or are subdued by a host peripheral regulatory
response, analogous to the peripheral regulatory
mechanisms that routinely control self-reactive clones
that escape thymic deletion in normal individuals. This
hypothesis reconciles with our data supporting partial
clonal deletion of donor reactive T cells in engrafted
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self-tolerance but requires experimental validation. If
true, it would open possibilities for new strategies for
facilitation of donor cell engraftment. A major ques-
tion is how these data relate to a large animal system
and the human. By translation of ontologic events
the period available for donor antigen presentation in
the thymus should be longer. This may provide a better
opportunity for donor antigen presentation in the thy-
mus or allow opportunity for manipulation of this pro-
cess to achieve more complete deletion of donor
reactive T lymphocytes or enhance the production of
donor specific T regulatory cells. In summary, our cur-
rent view from studies in the murine model is that the
level of engraftment is limited by host cell competi-
tion, whereas loss of engraftment and absence of chi-
merism is because of failure to overcome the adaptive
immune barrier.
CONSIDERATIONS FOR CLINICAL APPLICATION OF IUHCT
There have been approximately 50 reported cases of
IUHCT in humans over the past 20 years. Drawing
conclusions based on clinical experience in humans
has been difficult because of a large variety of target
diseases, donor cell sources, and transplantation proto-
cols. Not surprisingly, successes have largely been lim-
ited to cases of immunodeficiency syndromes in which
donor cells have a clear selective advantage over host
cells. In utero therapy for XSCID has been successful,
with at least 10 documented cases of cellular reconstitu-
tion with functional T cells [65-68,82,83]. However,
recipients manifest split chimerism with only the T
cell compartment engrafted similar to the results of
nonmyeloablative postnatal HSCT [84]. Thus far,
there is no proved advantage for prenatal treatment
of XSCID over neonatal transplantation. Attempts to
treat other immunodeficiency disorders such as chronic
granulomatous disease (CGD) or Chediak-Higashi
syndrome, have been unsuccessful thus far, as all sub-
jects were born without detectable engraftment [85-88].
The use of IUHCT for hemoglobinopathies has
also been attempted, but has thus far been largely
unsuccessful. There have been 12 attempts to treat b-
thalassemia in utero, with only 2 investigators report-
ing detectable postnatal engraftment [89-94], at least
1 of whom subsequently lost engraftment [66]. There
have been 3 reported attempts to treat a-thalassemia
by IUHCT [90-95,96], with 1 patient exhibiting mi-
crochimerism and tolerance to donor antigen by mixed
lymphocyte reaction [95]; however, all 3 patients re-
mained transfusion dependent. There have also been
3 reported attempts to treat sickle cell anemia; how-
ever, none have resulted in detectable engraftment
[88,96]. There have been 7 reported attempts to treat
metabolic storage diseases by IUHCT [85,91,97,98],
with 2 reports of engraftment [82,97], 1 of which ledto no clinical improvement and the other resulted in
prenatal death, likely because of GVHD.
Given this history, few recent attempts at IUHCT
have been reported, and many investigators have been
discouraged. However, the rationale remains compel-
ling, and there are lessons to be learned from this expe-
rience that may help guide future efforts. Many of the
historic attempts were ill advised for reasons that are
now recognized. Many of the transplants were per-
formed too late in gestation, or with donor cell sources
that would not be expected to succeed. For instance,
the use of highly enriched HSC as a donor source
has been unsuccessful in allogeneic experimental sys-
tems, and has been clinically unsuccessful, even when
performed under optimal circumstances. In addition,
the expectation that one could achieve therapeutic
levels of engraftment after IUHCT alone for diseases
like the hemoglobinopathies was somewhat naı¨ve
given what we now understand about the barriers to
engraftment.
At the present time, there are 2 clinical strategies
that may be successful in clinical application. The first
is IUHCT alone, which may be successful for selected
biologically favorable target disorders. The second is
IUHCT for donor-specific tolerance induction fol-
lowed by postnatal minimally conditioned HSCT
from the same donor. The latter approach holds the
most immediate promise for broad clinical application
of IUHCT because it requires only a minimal level of
chimerism to be successful, and because it would be
applicable to the majority of disorders that can be pre-
natally diagnosed and treated by postnatal HSCT.
Considerations for IUHCTAlone
The goal of this strategy is to achieve therapeutic
levels of engraftment with either single or multiple in
utero transplants. Based on our current understanding
of human immune and hematopoietic ontogeny, the
ideal timing of at least the first IUHCT would be at
11 to 14 weeks gestation. During this time the fetal
liver has active hematopoiesis, and thymic selection
is ongoing with very few mature lymphocytes present
in the thymus or peripheral circulation. Also, at this
time the fetus is very small,\35 g in weight, allowing
the opportunity to maximize the dose of donor cells. At
the present time, the only disorders that this strategy
can be contemplated for are disorders that offer either
a competitive advantage for donor cells, or perhaps
disorders that require only minimal levels of engraft-
ment for therapeutic success. Clearly, the most biolog-
ically favorable disease for treatment by IUHCT alone
remains XSCID. Other characterized mutations in
cytokine receptor signaling pathways (ie, Jak 3 or
ZAP-70) resulting in SCID should also be favorable
candidate diseases for IUHCT. Based on the available
clinical and experimental evidence, it is likely that any
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treated by IUHCT, using established protocols, with
results comparable to the reported results for XSCID.
Neonatal nonmyeloablative haploidentical HSCT re-
mains the standard for comparison for novel treat-
ments of XSCID. For IUHCT to be recommended
as an alternative therapy, a clear advantage for IUHCT
would need to be demonstrated. Ideally, clinical trials
of IUHCT for XSCID would be established, and the
results compared to early postnatal transplantation
protocols, to determine whether there is a biologic
advantage favoring IUHCT. Unfortunately, such tri-
als may not be possible because of the rarity of these
diseases and the perception by some that postnatal
therapy is adequate [84,99]. Another group of diseases
that could benefit from IUHCT are those in which
somatic mosaicism and in vivo selection have been
documented to occur. In these diseases there is pre-
sumably a survival advantage for the spontaneously
corrected cells [100]. Such correction has been noted
in adenosine deaminase SCID [101], Fanconi Anemia
[102], and Bloom Syndrome [103], the latter 2 of which
are chromosomal breakage syndromes. In both Fan-
coni Anemia and Bloom Syndrome mitotic recombi-
nation was documented as the molecular mechanism
of somatic reversion. This represents an experiment
of nature documenting the improvement in a disease
by clonal expansion of a single spontaneously cor-
rected HSC, and suggests that low-level engraftment
achieved in utero could eventually replace host hema-
topoiesis as progressive BM failure occurred. True
clinical cure of either disease is unlikely, as they are
associated with other pleiotropic manifestations, such
as an increased rate of malignancy that are unlikely
to be reversed by hematopoietic reconstitution alone.
Some diseases that are treatable with low levels of
chimerism include CGD, hyper IgM syndrome, and
leukocyte adhesion deficiency (LAD). It has been well
documented that CGD can be corrected by as few as
5% normal neutrophils [104], and in X-linked hyper
IgM syndrome, phenotypically normal carriers have
been identified in whom the normal gene has been pre-
dominately silenced [105]. LAD-1 results from muta-
tions in the leukocyte integrin CD18, which inhibits
the expression of the CD18/CD11 complex on the
cell surface and thus the ability of leukocytes to adhere
to the vessel wall and migrate to sites of infection [106-
109]. Recent studies in the analogous canine LAD
model (CLAD) have demonstrated that even low levels
of donor CD181 cell engraftment following nonmye-
loablative matched littermate BMT can reverse the le-
thal disease phenotype in CLAD [107,110-112]. We
have recently demonstrated correction of the CLAD
phenotype by IUHCT of haploidentical adult BM de-
rived cells in the canine model [113].
Specific nonhematopoietic disorders of bone me-
tabolism may also be attractive target disorders forIUHCT. A recent report of rescue of osteopetrotic
mice with the same mutation as approximately half of
human patients with the autosomal recessive diseases
by IUHCT is intriguing [114]. In this study, complete
phenotypic correction associated with osteoclast en-
graftment was achieved, despite the fact that an abun-
dance of host osteoclasts remained present that were
not functional. There is also interest in treatment of
Osteogenesis Imperfecta by prenatal replacement of
‘‘mesenchymal stem cells’’ (MSCs) or stromal progen-
itor cells and a clinical case has been reported [115].
The experimental basis for application of IUHCT
toward this disease, however, needs further develop-
ment. Engraftment of MSCs after intraperitoneal
transplantation in xenogeneic systems occurs but is
very low in frequency [116]. The premise that typical
MSCs isolated by plastic adherence can permanently
repopulate the osteoblast compartment has been chal-
lenged [117] by the observation that hematopoietic
cells and osteoblasts are derived from a common pro-
genitor in the non-plastic adherent fraction of BM.
The question is then whether IUHCT with BM cells
can engraft the osteoblast compartment.
IUHCT alone could potentially treat the above
disorders using currently available methodology and
optimized protocols. However, at best, low levels of
multilineage chimerism could be achieved. Ideally,
approaches to achieve more robust engraftment by
IUHCT will be developed (as discussed below). Until
that time, however, the most likely strategy in the near
future for IUHCT to treat many disorders is donor-
specific tolerance induction followed by postnatal
minimal conditioning HSCT.
IUHCT for Donor-Specific Tolerance Induction
followed by Postnatal Minimal Conditioning HSCT
As discussed earlier, low levels of mixed hemato-
poietic chimerism after IUHCT are associated with
donor specific tolerance. The exact level of chimerism
required may vary slightly with species, but is in the
1%-2% range. In the murine system, we have observed
that in the presence of microchimerism (\0.5%, donor
cells detectable only by PCR) approximately 1/3 of
animals are tolerant of donor skin grafts and nonreac-
tive by mixed lymphocyte reaction (MLR) [38,42].
Using the ability to enhance chimerism after IUHCT
by a minimal conditioning postnatal HSCT from the
same donor strain as the definition of tolerance, only
60% of animals with flow cytometrically detectable
chimerism of \1% were tolerant, whereas 100% of
animals with chimerism of .1% were tolerant [45].
Tolerance can be used as a platform to dramatically
enhance donor cell chimerism postnatally by nontoxic
approaches. We have demonstrated 3 such approaches
in the murine model, that is, low-dose total body irra-
diation (TBI) [44], donor lymphocyte infusion (DLI)
[43], and single-agent busulfan conditioning [45], all
736 D. Merianos et al.of which can increase donor chimerism to complete or
near complete levels with minimal or no toxicity. This
type of strategy is particularly well suited to the hemo-
globinopathies [40], where moderate levels of mixed
chimerism result in near complete replacement of cir-
culating red cells because of the relatively prolonged
half-life of normal red cells relative to diseased red
cells. In the large Italian experience with mixed chime-
rism in b-thalassemia patients, levels of bone marrow
chimerism of 25% have been associated with clinical
amelioration of b~-thalassemia major and isolated ob-
servations support similar levels for sickle cell disease
[118,119]. Currently, patients with sickle cell disease
and Thalassemia are rarely transplanted in the absence
of a matched sibling donor because of concern for
treatment related toxicity. The ability to induce toler-
ance by IUHCT to a haploidentical parent would
essentially create a matched donor circumstance, allow-
ing a relatively nontoxic HSCT in the neonatal period.
Obviously, if hemoglobinopathies can be treated,
many other disorders, including all of the disorders
discussed above in which a selective advantage exists
for donor cells or in which only minimal levels of en-
graftment are required for correction could also be
treated. At the present time it is likely that, with opti-
mal protocols, levels of chimerism required for toler-
ance induction can be achieved in human fetuses.
What are currently needed are studies in preclinical
large animal models that more closely approximate
human fetal biology to optimize transplant regimens
prior to human trials.
STRATEGIES TO IMPROVE ENGRAFTMENT
Consideration of IUHCT in the context of the
barriers discussed above suggests a number of strate-
gies by which higher levels of engraftment might be
achieved. These strategies fall into 3 broad categories
with significant overlap between them, which are: (1)
strategies to improve the receptivity of the host and
increase the number of donor HSC engrafted; (2)
strategies to provide a competitive advantage for donor
cells allowing expansion of donor cells after engraft-
ment; and (3) strategies to overcome the immune bar-
rier and, therefore, enhance the frequency of successful
engraftment.
Improvement in host receptivity awaits the develop-
ment of a method for highly selective, nontoxic myeloa-
blation in the fetus. This is, in our opinion, the single
development that would dramatically increase levels
of donor cell engraftment and make IUHCT alone
broadly applicable. The ability to selectively myeloa-
blate the host hematopoietic compartment would allow
donor cells to engraft and compete effectively after
transplantation. Lessdramatic improvement in receptiv-
ity might be achieved by nontoxic mobilization of host
cells into the circulation so that hematopoietic nicheswould be available for donor HSC to occupy. Although
theoretically attractive and powerful, there have been
no studies published thus far in which either of these
strategies have been successfully applied in the fetus.
Achieving a competitive advantage for donor cells
is a promising strategy that is unlikely to achieve ther-
apeutic levels of engraftment after IUHCT alone, but
is very likely to be the key to achieving the incremental
increase in engraftment needed for consistent and sta-
ble donor-specific tolerance induction. The simplest
manipulation is to increase or maximize the number
of donor cells transplanted. This can be approached
by increasing the number of HSC within the donor in-
noculum, performing multiple transplants, or both.
Similar to observations in the nonmyeloablated synge-
neic mouse model discussed previously, both increases
in cell dose and multiple transplants have been shown
experimentally to incrementally increase engraftment
after IUHCT [120]. Ex vivo manipulation of donor
cells to selectively improve their competitive capacity
after transplantation is an attractive strategy because
it can be done prior to IUHCT, provides inherent se-
lectivity for donor cells, and should avoid toxicity to
the fetus. For instance, we recently demonstrated
that blockade of the dipeptidyl peptidase CD26 [121]
on donor cells increased homing of donor cells to the
fetal liver, improved their competitive capacity relative
to nonblocked cells, and resulted in increased short-
and long-term levels of chimerism, presumably via
a mechanism of increased SDF-1a expression on do-
nor cells [51]. The demonstration that transient ma-
nipulation of a single chemokine interaction can
result in improvements in engraftment is encouraging,
as there are many steps in the homing and engraftment
process that could potentially be manipulated, singly
or in combination, to significantly improve engraft-
ment. Other manipulations that selectively influence
expression of homing receptors and engraftment in-
clude preincubation of donor cells with hematopoietic
growth factors [122] and likely cotransplantation with
stroma. The use of stromal cotransplantation has in-
creased short- and long-term donor cell expression
in the sheep model [123,124]; however, the mechanism
remains to be elucidated.
The recognition of an immune barrier suggests
potential immune-based strategies for application to
IUHCT that might prevent loss of engraftment. How-
ever, intelligent design of such strategies awaits better
definition of the nature and mechanism of the immune
barrier. Historically, there have been a number of stud-
ies documenting the important role of donor T cells in
engraftment. The concept that immune cells within the
donor inoculum might facilitate engraftment is sup-
ported by observations of failure of engraftment of T
cell-depleted or highly enriched HSC in multiple ani-
mal species and restoration of low level engraftment
by the addition of T cells [30,125-127]. However, no
In Utero Hematopoietic Stem Cell Transplantation 737dose of T cells has been identified that can meaning-
fully increase engraftment without the associated risk
of GVHD. The strategy of inducing a graft-versus-
hematopoietic effect by adding T cells from donors
immunized against the recipient and treated ex vivo
to reduce the likelihood of GVHD has been attempted
in 2 studies using different techniques for T cell prep-
aration [39,128]. In both studies proof of principle was
demonstrated by the achievement of complete donor
hematopoietic chimerism in selected animals. How-
ever, there was clear evidence of GVHD in both stud-
ies. The importance of these studies is that they
demonstrate that if a more specific targeting strategy
for host hematopoietic cells could be achieved by donor
immune cells, very high levels of donor engraftment are
possible. Such specificity might be possible, for exam-
ple, by targeting hematopoietic specific minor histo-
compatibility antigens [129]. Finally, if graft rejection
represents either failure of adequate thymic donor
reactive lymphocyte deletion, and/or failure of donor
specific T regulatory cell generation in the thymus,
strategies related to improving the quantity and quality
of donor antigen presentation in the thymus might be
appropriate. Tipping the balance toward more com-
plete donor reactive lymphocyte deletion or more ro-
bust generation of donor specific T regulatory cell
generation may prevent rejection and allow consistent
and reliable engraftment at levels that are adequate
for donor specific tolerance induction.
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